Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Vernalis (VER)

London
Currency in GBP
Disclaimer
6.170
0.000(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
6.1406.170
52 wk Range
0.0006.170
Prev. Close
6.17
Open
6.14
Day's Range
6.14-6.14
52 wk Range
0-0
Volume
0
Average Volume (3m)
441,631
1-Year Change
0%
Shares Outstanding
526,986,000
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about VER?
Vote to see community's results!
or

Vernalis Company Profile

Vernalis Limited, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company offers Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It also holds licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. Vernalis Limited was formerly known as Vernalis plc. The company was incorporated in 1988 and is headquartered in Cambridge, United Kingdom. Vernalis Limited operates as a subsidiary of Ligand Holdings Uk Ltd

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.